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 The introduction of immunotherapy with checkpoint inhibitors into clinical practice has radically changed the treatment 
and prognosis of patients with cancer. This treatment is also extensively studied in patients diagnosed with advanced 
sarcomas, where the number of effective therapies is limited. The following review presents the latest reports on the use 
of immunotherapy in the treatment of patients with sarcomas.
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Sarcomas are rare malignant tumors comprising about 1% of all 
adult cancers. Sarcomas can be found both in the soft tissues 
(STS) and bones (BS). Moreover, they affect all age groups, with 
a median age for STS patients of about 50-year-old, but much 
younger for bone tumors such as osteosarcoma or Ewing 
sarcoma. The cornerstone of therapy of locally advanced sarco-
mas is surgery, in most cases used with adjuvant radiotherapy 
and chemotherapy. However, metastatic recurrence is often 
found and concerns even 50% of sarcoma cases, depending 
on the subtype and initial tumor stage. As there are more 
than 60 subtypes of sarcoma, with different prognosis, risk of 
recurrence and sensitivity to systemic therapy, heterogeneity 
within this group of tumors and its rarity make it extremely 
difficult to develop a successful clinical trial for this group of 
patients. Furthermore, research undertaken over recent years 
has proven this thesis with several negative phase three trials 
for new therapies in sarcomas [1, 2].  
Immunotherapy is based on the idea that a patient’s im-
mune system can be stimulated or enhanced so as to attack 
malignant tumors. As an anecdote, it is worth recalling that one 
of the first successful examples of the use of immunotherapy 
in cancers was described more than 100 years ago in sarcoma 
patients. They were treated by Dr. William B. Coley, who injected 
streptococcal organisms into patients with inoperable cancer, 
with some success; this consequently resulted in him being 
given the title of the “Father of Immunotherapy” [3]. From 
that time, much has changed, and in recent years we have 
witnessed a real revolution in the use of immunotherapy to 
treat malignant tumors. We owe this breakthrough mainly 
to the introduction into clinical practice of drugs from the 
checkpoint inhibitors group, which have shown improved 
rates of patient survival with melanoma, lung cancer, or kidney 
cancer, among others.
Knowledge about the immune profile of sarcomas is still 
limited. Several important studies on this topic have already 
been published, although their results can sometimes be con-
fusing because of the heterogeneity of this group of tumors 
[4]. This review will present some of the latest immunotherapy 
achievements in sarcoma, focusing on trails with checkpoint 
inhibitors in less selected groups of patients and in specific 
subtypes, where it seems that this type of therapy is most 
successful. 
Immune checkpoints in sarcomas
One of the first studies analyzed the clinical impact of intra-
-tumoral infiltration of PD1-positive lymphocytes and PD-L1 
expression in tumor cells in 105 cases of STS. Intra-tumoral 
infiltration of PD1-positive lymphocytes and PD-L1 expression 
was seen in 65% and 58% of STS, respectively. Both PD1-po-
sitivity and PD-L1 expression were significantly associated 
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with advanced clinicopathological parameters such as higher 
clinical stage, distant metastasis, higher histological grade, 
a low differentiation of tumor and tumor necrosis. Moreover, 
both PD1-positivity and PD-L1 positivity were independent 
prognostic indicators of overall survival (OS) and event-free 
survival (EFS) of STS by multivariate analysis. The combined 
pattern of PD1- and PD-L1-positivity was also an independent 
prognostic indicator for OS and EFS by multivariate analysis. 
The patents with a PD1+/PD-L1+ pattern had the shortest 
survival time [5]. A study from the Memorial Sloan Kettering 
Cancer Center evaluated PD-L1 expression by immunohisto-
chemistry in 50 sarcoma specimens and quantified tumor-
-infiltrating lymphocytes (TIL). Immunohistochemical staining 
for CD3, CD4 (helper T cells), CD8 (cytotoxic T cells), foxp3 
(regulatory T cells), and PD-1 and PD-L1 expression, and mul-
tiplex immunohistochemistry for CD3/PD-1, CD3/CD8, and 
CD3/CD4/foxp3 were performed. Lymphocyte infiltration was 
observed in 98% of cases, and macrophage infiltration in 90%. 
“Low-density” TILs was defined as below 5% and “high-density” 
as above 5%; they noted that 27 patients (54%), mainly those 
with leiomyosarcoma (LMS, 3 of 4), synovial sarcoma (4 of 5), 
and chondrosarcoma (1 of 1), had low-density TILs; another 
22 patients (44%), mainly those with gastrointestinal stromal 
tumors (9 of 14), had high-density TILs. Tumor, lymphocyte, 
and macrophage PD-L1 expression was 12%, 30% and 58%, 
respectively, with the highest frequency of PD-L1 positivity 
seen in gastrointestinal stromal tumors (4 of 14). There was 
no association between clinical features, overall survival, and 
PD-L1 expression in tumor or immune infiltrates [6]. 
In tumor tissues collected by biopsy or surgical resection, 
56 osteosarcoma patients (17%) showed PD-L1 expression. 
PD-L1 expression was not associated with poor prognosis. 
PD-L1 immunoexpression was significantly associated with the 
infiltration of CD3+ T cells, CD4+ T cells, and CD8+ T cells [7]. In 
Ewing’s sarcoma, CD8+ TILs were detected in 15% of samples 
from 370 patients, but this finding was not correlated with 
the histological subtypes, location of the tumor, or PD-1 and 
PD-L1 expression, and it did not impact progression-free su-
rvival or overall survival. PD-1 was expressed in 26% of tumors. 
Histological subtypes were not correlated with PD-L1 or PD-1 
positivity. Metastatic tumors had higher expression of PD-L1 
(p < 0.0001). Lesions with elevated proliferation index (Ki-67) 
were associated with higher PD-L1 expression (p =  0.049). 
In terms of prognosis, no significant association was found 
between PD-L1 expression and progression-free survival (PFS) 
or overall survival (OS). However lack of PD-1 expression in 
tumor cells was correlated with both poor PFS (p = 0.02) and 
poor OS (p = 0.004) [8]. In chondrosarcoma, PD-L1 expression 
was absent in conventional (n = 119), mesenchymal (n = 19) 
and clear cell (n = 20) chondrosarcomas. 41% (9 of the 22) of 
dedifferentiated chondrosarcomas displayed PD-L1 positivity. 
TILs were detectable and correlated with PD-L1 expression, 
being highly expressed in dedifferentiated chondrosarcomas. 
PD-L1 expression was also correlated with positive HLA class I 
expression, but not with a patient’s survival [9].
Overall, it seems that the expression and clinical associa-
tions were found to be subtype dependent. A study of 208 
sarcoma patients, programmed cell death-1 (PD-1), program-
med death ligand-1 (PD-L1) and CD8 were assessed in tumors. 
Primary untreated osteosarcoma (n = 46), Ewing sarcoma 
(n = 32), alveolar rhabdomyosarcoma (n = 20), embryonal 
rhabdomyosarcoma (n = 77), synovial sarcoma (n = 22) and 
desmoplastic small round cell tumors (DSRCT) (n = 11) were 
examined immunohistochemically. PD-L1 expression was 
predominantly detected in alveolar and embryonal rhabdo-
myosarcomas (15% and 16%, respectively). In the alveolar 
subtype, PD-L1 expression was associated with better OS, EFS 
and metastases-free survival. PD-1 expression on lymphocytes 
was predominantly seen in synovial sarcomas (18%). High 
levels of CD8+ lymphocytes were predominantly detected in 
osteosarcomas (35%) and associated with worse event-free 
survival in synovial sarcomas. Ewing sarcoma and DSRCTs 
showed PD-1 on tumor cells instead of on tumor-infiltrating 
lymphocytes [10].
Using transcriptomic analysis of the microenvironment 
cell population,  measuring the expression of eight immune 
and two stromal cell populations, sarcomas were classified into 
five different sarcoma immune classes (SIC). Each SIC exhibited 
a different profile, from A (immune desert-cold tumors), which 
showed the lowest expression of gene signatures of immune 
cells and vasculature expression, to E (immune and tertiary 
lymphoid structures) with the highest expression of genes 
related to immune cells. In the middle, C (vascularized) was 
characterized by a high expression of endothelial related ge-
nes. SIC B and D have expressed mixed profiles between A and 
C or C and E. This grouping of sarcomas into these five classes 
based on different profile expressions of tumor microenviron-
ment also had a prognostic impact. So, SIC A patients showed 
poorer overall survival than SIC D (p = 0.048) or SIC E (p = 0.025). 
Furthermore, this genomic immune signature had a predictive 
role in a prospective series treated with pembrolizumab. The 
overall response rate (ORR) was 50%, 25%, 22%, 0% and 0% 
for SIC E, D, C, B and A respectively. Patients harboring SIC E 
had significantly higher ORR with pembrolizumab (p = 0.026). 
Patients grouped as SIC E only represented 17.8% of cases. 
A more detailed analysis revealed a significant correlation of 
survival with B-cell lineage signature, whereas CD8+ signature 
did not significantly correlate with survival [11, 12].
Clinical trials 
A large study of immunotherapy in sarcomas was published in 
2017 (SARC028 Trial) [13]. In this two-cohort, single-arm, open-
-label, phase 2 study, 86 patients were enrolled with soft-tissue 
sarcoma or bone sarcoma. Patients with soft-tissue sarcoma 
had to be aged 18 years or older to enroll; patients with bone 
sarcoma could enroll if they were aged 12 years or older. 
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Patients had histological evidence of metastatic or surgically 
unresectable locally advanced sarcoma, and had received up to 
three previous systemic anticancer therapy lines, with at least 
one measurable lesion according to the Response Evaluation 
Criteria In Solid Tumors version 1.1 (RECIST). Included subtypes 
were leiomyosarcoma, poorly differentiated or dedifferentiated 
liposarcoma, undifferentiated pleomorphic sarcoma, synovial 
sarcoma, Ewing’s sarcoma, osteosarcoma and dedifferentiated 
or mesenchymal chondrosarcoma. All patients were treated 
with 200 mg of intravenous pembrolizumab every three weeks. 
The primary endpoint was the investigator-assessed objective 
response. One-third of the patients previously received three 
lines of systemic therapy. The median follow-up was 17.8 mon-
ths (IQR 12.3–19.3). 
Seven (18%) out of the 40 patients with STS had an ob-
jective response, including four (40%) of the ten patients 
with undifferentiated pleomorphic sarcoma, two (20%) of 
the ten patients with liposarcoma, and one (10%) of the 
ten patients with synovial sarcoma. One (10%) patient with 
undifferentiated pleomorphic sarcoma – a woman aged 50 
years with primarily pulmonary lesions whose response lasted 
for longer than 13 months – achieved a confirmed complete 
response. Responses in patients with soft-tissue sarcoma 
were generally durable, with a median duration of 33 weeks 
(IQR 23–49). No patients with leiomyosarcoma (n=10) had an 
objective response. In the bone sarcoma group, a confirmed 
partial response was observed in one (5%) of the 22 patients 
with osteosarcoma and one (20%) of the five patients with 
chondrosarcoma. No patient with Ewing’s sarcoma had an 
objective response. 37 (93%) of the 40 evaluable patients with 
soft-tissue sarcoma had a progression event (i.e., progressed 
or died), and median progression-free survival (PFS) was 18 
weeks (95% CI 8–21). 
The 12-week PFS was 55% (95% CI 40–70), which was si-
gnificantly higher than the threshold of 40% expected from an 
active regimen in patients with soft-tissue sarcoma (p = 0.039). 
The median PFS was 30 weeks (95% CI 8–68) for patients with 
undifferentiated pleomorphic sarcoma (seven [70%] of whom 
had a progression event), and 12-week PFS was 70% (42–98). In 
ten patients with liposarcoma (all of whom had a progression 
event), the median PFS was 25 weeks (95% CI 8–42), and the 
12-week PFS was 60% (30–90). The median OS for patients 
with soft-tissue sarcoma was 49 weeks (95% CI 34–73); 25 
patients died because of disease progression. The median OS 
for patients with undifferentiated pleomorphic sarcoma had 
not been reached at the time of this analysis; four patients 
had died. 38 (95%) of the 40 patients with bone sarcoma 
had a progression event; data for one (3%) patient has been 
censored. The median PFS was eight weeks (95% CI 7–9). 25 
(63%) patients with bone sarcoma died because of disease 
progression; the median OS was 52 weeks (95% CI 40–72). The 
median OS was not reached in patients with chondrosarcoma. 
The median duration of response was 43 weeks. 
The most frequent grade 3 or worse adverse events were 
anemia (six [14%]), a decreased lymphocyte count (five [12%]), 
prolonged activated partial thromboplastin time (four [10%]), 
and decreased platelet count (three [7%]) in the bone sarcoma 
group;  anemia, decreased lymphocyte count and prolonged 
activated partial thromboplastin time was evident in the soft-
-tissue sarcoma group (three [7%] each). Nine (11%) patients 
(five [12%] in the bone sarcoma group and four [10%] in the 
soft-tissue sarcoma group) had treatment-emergent serious 
adverse events (SAEs), five of whom had immune-related SAEs, 
including two with adrenal insufficiency, two with pneumonitis 
and one with nephritis.
As the results of the treatment seemed to be best in the 
group of patients with undifferentiated pleomorphic sarco-
ma (UPS) and liposarcoma (LPS), the investigators decided 
to have an expansion cohort in these subtypes. The results 
were presented at the American Society of Clinical Oncology 
conference in 2019. 30 patients were additionally enrolled  in 
each of the 2 expansion cohorts for a total of 40 UPS and 40 LPS 
patients. The primary endpoint was the investigator-assessed 
response by RECIST v1.1. Secondary endpoints were safety, PFS, 
the 12-week PFS rate and OS. An ORR of 25% was considered 
clinically meaningful, and <10% was considered to lack effi-
cacy. The use of pembrolizumab was considered a success if 8 
or more of the 40 enrolled patients had a partial response (PR) 
to therapy or better (1-sided α = 0.042, 82% power). The ORR 
in the UPS cohort was 23% (9/40), with an additional 5/30 PRs 
observed in the expansion cohort In the LPS cohort, the ORR 
was 10% (4/39 evaluable patients), with an additional 2/30 PR 
observed (total 4 PR). The median PFS for the UPS group was 
3 months (95% CI 2–5) and 2 months (95% CI 2–4) for the LPS 
group. The 12-week PFS rate was 50% in UPS (95% CI 35–65) 
and 44% in LPS (95% CI 28–60). The UPS group had a median 
OS of 12 months (95% CI 7–34) and 13 months (95% CI 8–NR) 
for the LPS group [14].
Results of the translational research from the study were 
recently published. Pretreatment (available for 78 patients) 
and 8-week on-treatment (from 68 patients) tumor biopsies 
were stained for PD-L1 and multiplex immunofluorescence 
panels. The density of positive cells was quantified to deter-
mine associations with the anti-PD-1 response. It turned out 
that patients that responded to pembrolizumab were more 
likely to have higher densities of activated T cells (CD8 + CD3 
+ PD-1+) and an increased percentage of tumor-associated 
macrophages expressing PD-L1 pre-treatment compared with 
non-responders. Pre-treatment tumors from responders also 
exhibited higher densities of effector memory cytotoxic T cells 
and regulatory T cells than non-responders. Moreover, a higher 
density of cytotoxic tumor-infiltrating T cells at baseline corre-
lated with better PFS [15].
Additionally, the immunotherapy combination  was stu-
died in sarcomas. An open-label, unblinded, non-comparative 
multi-center randomized phase II study enrolled 96 sarcoma 
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Anthracycline-based therapy is a standard first-line tre-
atment for most patients with advanced and metastatic 
sarcomas. Although multiple trials have attempted to show 
improved outcomes in patients with soft-tissue sarcoma over 
doxorubicin monotherapy, each has fallen short of demonstra-
ting improved outcomes. A nonrandomized clinical trial used 
a 2-stage phase 2 design and was performed to assess the effi-
cacy and safety of doxorubicin and pembrolizumab in patients 
with advanced anthracycline-naive sarcoma [17]. Patients were 
adults with good performance status and end-organ function. 
Patients with all sarcoma subtypes were allowed to enroll with 
the exception of those with osteosarcoma, Ewing sarcoma, 
and alveolar and embryonal rhabdomyosarcoma. Two dose 
levels of doxorubicin (45 and 75 mg/m2) were tested for safety 
combined with pembrolizumab. The patients’ initial cycle was 
pembrolizumab (200 mg administered intravenously) alone. 
Cycles were 21 days. Starting with cycle 2, doxorubicin was 
given before pembrolizumab, on the same day, every 3 weeks, 
for up to 6 cycles. After cycle 7, pembrolizumab treatment 
continued for up to 2 years. The primary endpoint was ORR. 
Secondary endpoints were PFS and OS. Correlative studies 
included immunohistochemistry, gene expression and serum 
cytokines. 
A total of 37 patients (22 men, 15 women) were treated. 
The median patient age was 58,4 (ranging from 25–80) years. 
The most common histologic subtype was leiomyosarcoma 
(11 patients). Doxorubicin plus pembrolizumab was well-tole-
rated without significant unexpected toxic effects. The ORR was 
19%, and 59% of patients had stable disease. Two of the three 
patients with UPS and two of the four patients with dediffe-
rentiated liposarcoma had durable response to therapy. Three 
patients with chondrosarcoma had tumor regression, including 
one conventional chondrosarcoma with a 26% decrease in size. 
Median PFS was 8.1 (95% CI 7.6–10.8) months. The PFS rates at 
12 and 24 weeks were 81% (95% CI 64–90%) and 73% (95% CI 
56–84%), respectively. At 12 months, the PFS was 27% (95% CI 
14–42%). The median OS was 27.6 (95% CI 18.7–not reached) 
months at the time of this analysis. Immunohistochemistry was 
evaluable for 29 patients; 66% had PD-L1 expression scores 
of 0, reflecting a low level of PD-L1 expression. Expression 
of PD-L1 was not associated with PFS or OS. Tumor-infiltra-
ting lymphocytes were present in 21% of evaluable tumors 
and associated with inferior PFS (log-rank p = 0.03). This was 
confirmed in a multivariate Cox regression analysis adjusted 
for age, sex and the number of prior therapies (p = 0.04). No 
dose-limiting toxic effects were observed. The most common 
toxic effects were nausea (n = 32) and fatigue (n = 21). No grade 
5 toxic effects were seen; the only attributable grade 4 toxic 
effects were neutropenia (n = 6), leukopenia (n = 1) and febrile 
neutropenia (n = 1), all of which resolved. Two patients had 
grade 3 reductions in ejection fraction attributable to doxoru-
bicin. Notable pembrolizumab-related toxic effects included 
grade 3 adrenal insufficiency (n = 1) and hypothyroidism (n = 7). 
patients [16]. Patients received either nivolumab 3 mg/kg 
every two weeks or nivolumab 3mg/kg and ipilimumab 
1mg/kg every three weeks for four doses followed by nivo-
lumab (3 mg/kg) every two weeks thereafter. Patients with 
a central pathology confirmation of sarcoma were inclu-
ded. They had to be at least 18 years old to enroll and have 
evidence of metastatic or unresectable disease and good 
performance status. Patients had to have received at least 
one previous systemic therapy line. The primary endpoint 
was the confirmed objective response rate (ORR). Secondary 
endpoints included safety, the duration of the response, 
clinical benefit rate, PFS and OS.  
Patients were heavily pre-treated, with 61% of patients 
receiving at least three prior chemotherapy lines. The most 
common enrolled sarcoma types across both arms included: 
bone nine (10.6%), LMS 29 (34.1%), LPS five (5.9%), spindle 
cell sarcoma 11 (12.9%), UPS 11 (12.9%) and other 10 (11.7%). 
Among the 38 patients that received nivolumab monothe-
rapy, the confirmed ORR was 5% [92% CI 1–15%]. Responses 
occurred in the following histological subtypes: alveolar soft 
part sarcoma (ASPS), non-uterine LMS and sarcoma NOS. For 
the 38 patients that received combination therapy, the confir-
med ORR was 16%, (92% CI 7–29%). Responses occurred in UPS, 
LMS, myxofibrosarcoma and angiosarcoma. The median PFS 
was 1.7 months [n = 42, 95% CI 1.4–4.3 months) for monothe-
rapy. The median OS was 10.7 months (n = 42, 95% CI 5.5–15.4). 
The 12-month OS rates were 40,4% (n = 12, 95% CI 27.2–59.9%). 
For combination arm, the median PFS was 4.1 months [n = 41, 
95% CI 2.6–4.7) and the median OS was 14.3 months (n = 41, 
95% CI 9.6–not estimable). The 12-month OS rate for combina-
tion therapy was 54.6% (n = 41, 95% CI 41–72,7%). In the mo-
notherapy arm, the most common grade 3 or worse adverse 
events included anemia (four – 10%), decreased lymphocyte 
count (three – 7% each) and dehydration, increased lipase, 
pain, pleural effusion, respiratory failure, secondary benign 
neoplasm and urinary tract obstruction (two – 5% each.) In 
the combination arm, the most common grade 3 or worse 
adverse events included: anemia (seven – 17%), hypotension 
(four – 10%), pain, and urinary tract infection (three – 7%). 
Treatment-related serious adverse events on the monotherapy 
arm occurred in eight patients and included anemia, anorexia, 
dehydration, decreased platelet count, diarrhea, fever, incre-
ased creatinine, and pleural effusion (one – 2% each). On the 
combination arm, treatment-related serious adverse events 
occurred in 11 patients. Three patients – 7% patients had 
adrenal insufficiency, two patients – 5% had increased alanine 
aminotransferase, two patients– 5% with hyponatremia, one 
patient– 2% each experienced anemia, increased aspartate 
aminotransferase, fatigue, pain and pruritus.
In an attempt to improve the modest results of immuno-
therapy alone in the treatment of advanced sarcomas, efforts 
have also been made to combine this treatment with other 
drugs commonly used in this indication. 
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This result is impressive for patients with advanced sarcoma, 
but of course, this result must be confirmed in a phase III trial.
Another attempt is supported by evidence that tumor 
angiogenesis promotes immunosuppression. A phase Ib/II trial 
tested the double inhibition of angiogenesis (sunitinib) and 
PD-1/PD-L1 axis (nivolumab). This single-arm, phase Ib/II trial 
enrolled adult patients with selected subtypes of sarcoma[18]. 
Phase Ib established two dose levels: level 0 with sunitinib 37.5 
mg daily from day 1, plus nivolumab 3 mg/kg intravenously 
on day 15, and then every 2 weeks; and level – 1 with sunitinib 
37.5 mg for the first 14 days (induction) and then 25 mg per day 
plus nivolumab on the same schedule. The primary endpoint 
was to determine the recommended dose for phase II (phase 
I) and the 6-month progression-free survival rate, according to 
RECIST in Solid Tumors 1.1 (phase II). 68 patients were enrolled 
and treated with the experimental compounds: 16 in phase 
Ib and 52 in the STS cohort of phase II. The recommended 
dose of sunitinib for phase II was 37.5 mg as induction and 
then 25 mg combined with nivolumab. The 6-month PFS, 
according to central and local assessments, was 48% (95% CI 
41–55) and 51% (95% CI 44–58), respectively. The median PFS 
for central and local assessments was 5,6 months (3.0–8.1) and 
6 months (3.1–9), respectively. Remarkably, the proportion of 
patients alive at 12 and 18 months was 75% (95% CI 68–81) 
and 67% (95% CI 59–74), respectively, and the median OS was 
24 months (95%CI NA). 
The central radiological assessment according to RECIST 
reported 1 complete response in 46 evaluable patients (2%), 5 
partial responses (11%), 33 stabilizations (72%) and 7 progres-
sions (15%). A complete response was observed in one patient 
with angiosarcoma and partial response in patients diagnosed 
with ASPS (n = 2), angiosarcoma (n = 1), extraskeletal myxoid 
chondrosarcoma (n = 1) and synovial sarcoma (n = 1). Central 
assessment, according to Choi criteria, showed 25 patients 
with partial response (63%), 10 with stable disease (25%), and 
5 with progressive disease (12%). According to RECIST, the 
response assessment showed a significant prognostic diffe-
rence for PFS and OS; by contrast, the Choi assessment only 
had prognostic relevance for PFS. Adding the 12 evaluable STS 
cases of phase I to the 46 evaluable patients with STS in phase 
II, the RECIST Overall Response Rate (ORR) was 21% (12 out of 
58). The 18-month OS proportion was 100%, 75%, and 44% for 
those with a response, stable disease, and progressive disease, 
according to RECIST, respectively (p = 0.01). 
The most frequent treatment-related toxicities per subject 
in phase II were fatigue in 33 of the 52 patients (63,5%) and 
increased aspartate aminotransferase (AST) in 25 out of 52 
patients (48%). The most common reported grade 3 or 4 side 
effects were transaminitis in 9 out of 52 patients (17.3%) and 
neutropenia in 6 out of 52 patients (11.5%).
Alveolar soft part sarcoma (ASPS) is an exceedingly rare 
STS subtype inherently resistant to cytotoxic chemotherapy. 
It usually affects adolescents and young adults and presents 
early with widespread metastases that are ultimately fatal. The 
conserved translocation of the ASPSCR1-TFE3 fusion gene in 
ASPS leads to aberrant transcription of downstream target 
genes, including HIF-1α, which upregulates proangiogenic 
factors, including VEGF. Tyrosine-kinase inhibitors are the most 
active treatment to date for patients with ASPS, although most 
patients ultimately develop resistance and die due to the dise-
ase [19, 20]. This subtype is interesting because, compared to 
other sarcomas, it is characterized by its exceptional sensitivity 
to immunotherapy treatment. There are many case reports of 
patients diagnosed with advanced ASPS who have been suc-
cessfully treated with checkpoint inhibitors, including the case 
of a patient treated in the clinic where the author works [21, 22]. 
The phase II trial with atezolizumab monotherapy, a monoc-
lonal antibody directed against a ligand of a PD-L1, proved to 
be a success in this setting. The results were presented during 
the Connective Tissue Oncology Society Annual Conference in 
2018. 22 patients with advanced, metastatic ASPS were enrol-
led in the trials; most of them had previously undergone other 
therapies. According to RECIST criteria, a partial response was 
confirmed in 9 patients, disease stabilization in 9 patients and 
disease progression in 1 patient. In the 3 other patients treated, 
it was too early to make any evaluations [23]. The summary 
of studies in ASPS with immunotherapy is shown in table I. 
A single-arm, phase 2 study was conducted on the safety 
and efficacy of the antiangiogenic drug axitinib (VEGF inhibi-
tor) plus pembrolizumab in patients with advanced sarcomas, 
including alveolar soft-part sarcoma [24]. Patients were eligible 
if they were aged 16 years or older and had histologically con-
firmed advanced or metastatic sarcomas, including alveolar 
soft-part sarcoma (ASPS – who constituted 36% of the whole 
group of 33 patients); an ECOG performance status of 0–1; 
and disease progression after previous treatment with at least 
one line of systemic therapy (unless no standard treatment 
existed or the patient declined therapy). The first five patients 
were enrolled in a lead-in cohort and were given axitinib 5 mg 
orally, twice daily, and pembrolizumab 200 mg intravenously 
for 30 min on day 8 and every 3 weeks for cycles of 6 weeks for 
up to 2 years. After that, patients received escalating doses of 
axitinib (2–10 mg) plus a flat dose of pembrolizumab according 
to the schedule above.  The 3-month PFS for all patients was 
65.6% (95% CI 46.6–79.3), and the median PFS was 4.7  months 
(95% CI 3–9.4). The 6-month PFS was 46.9% (95% CI 29.2–62.8) 
and the 12-month PFS was 27.5% (13.4–43.6). The median ove-
rall survival for all 33 patients was 18.7 months (95% CI 12–not 
reached) with a 1-year overall survival of 72% (95% CI 53–84.4). 
Of the 32 patients evaluable for objective response, none 
achieved a complete response. Eight (25%, 95% CI 12.1–43.8) 
achieved a partial response at any point during treatment, 
and nine (28%) achieved stable disease, so the proportion 
of patients who achieved a clinical benefit was 53 % (n = 17; 
95% CI 35–70.5). The median duration of response was 29 we-
eks (IQR 21.8–76.5), and the median time to achieve partial 
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response was 19,4 weeks (IQR 12.8–31.4). Most responses 
occurred in patients with ASPS, with six of the eleven evaluable 
patients with ASPS achieving a partial response (54.5%, 95% 
CI 24.6–81.9), and two (18%) of the eleven achieving stable 
disease, so the proportion of patients who achieved a clinical 
benefit was 72.7% (n = 8; 95% CI 32.3–92.7). The median time 
to partial response in patients with ASPS was 25.1 weeks (IQR 
12.7–34.3). In addition, partial responses were observed in two 
patients, one with conventional type epithelioid sarcoma and 
one with soft tissue leiomyosarcoma, and minor responses 
(a decrease in the size of the target lesion of less than 30%) in 
three patients, one with soft tissue leiomyosarcoma, one with 
synovial sarcoma and one with high-grade undifferentiated 
pleomorphic sarcoma. 
The toxicity profile of axitinib plus pembrolizumab the-
rapy was consistent with the drugs’ previous clinical trials as 
monotherapy. Treatment-related toxicity occurred in only 
two (40%) of the five patients in the safety lead-in cohort, 
and no application of the early stopping rule was needed 
throughout the study. Treatment-related grade 3 or 4 ad-
verse events occurred in 13 (39%) of the 33 patients, and 
grade 3 or 4 autoimmune, toxic effects in five (15%) patients. 
The most common treatment-related adverse events of any 
grade included fatigue (26–79%), oral mucositis (23–70%), 
hypothyroidism or hyperthyroidism (21–64%), nausea or 
vomiting (22–67%), nasopharyngeal congestion (18–55%), 
and diarrhoea (19–58%). Serious treatment-related adverse 
events occurred in seven (21%) of the 33 patients, including 
autoimmune colitis, transaminitis, pneumothorax, hemop-
tysis, seizures and hypertriglyceridemia.
Conclusion
The rarity and heterogeneity within sarcoma groups have 
contributed to the slow development of effective new the-
rapies; outcomes for patients with advanced stages of the 
disease remain poor. The progress of immunotherapy, mainly 
with the development of checkpoint inhibitors, has been 
spectacular and revolutionized everyday oncology practice 
over the last few years. Naturally, this approach is also being 
studied in sarcomas, with some success, as has been shown 
in this review. It is worth emphasizing that immunotherapy in 
sarcomas is also studied in other aspects, such as vaccines or 
adoptive cell therapy. This approach makes particular sense 
in some of the STS subtypes, although so far, evidence of 
their effectiveness is limited [12]. That said, the author does 
not doubt that in the coming years there will be optimistic 
news on breakthrough therapies for patients with advanced 
sarcomas, as has happened, for example, with melanoma. The 
development of immunotherapy will also undoubtedly, in this 
case, contribute to this.
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